Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1769 - Initial treatment and survival in a national unselected Danish cohort of 4161 patients with pancreatic cancer.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Louise Rasmussen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

L.S. Rasmussen1, B. Vittrup2, M. Ladekarl3, P. Pfeiffer4, M.K. Yilmaz5, L.Ø. Poulsen1, K. Østerlind6, H. Skuladottir7, C.P. Hansen8, M.B. Mortensen9, F.V. Mortensen10, M. Sall11, U.G. Falkmer5, C. Fristrup12

Author affiliations

  • 1 Department Of Oncology, Clinical Cancer Research Center, Aalborg University Hospital; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, 9000 - Aalborg/DK
  • 2 Department Of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen/DK
  • 3 Department Of Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 4 Department Of Oncology, Odense University Hospital, Odense/DK
  • 5 Department Of Oncology, Clinical Cancer Research Center, Aalborg University Hospital; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg/DK
  • 6 Department Of Oncology, North Sealand Hospital, Hillerød/DK
  • 7 Department Of Oncology, Herning Hospital, Herning/DK
  • 8 Department Of Surgical Gastroenterology, Rigshospitalet, Copenhagen University Hospital, Copenhagen/DK
  • 9 Department Of Surgery, Odense Pancreas Center (OPAC), Odense University Hospital, Odense/DK
  • 10 Department Of Surgical Gastroenterology, Aarhus University Hospital, Aarhus/DK
  • 11 Department Of Surgical Gastroenterology, Aalborg University Hospital, Aalborg/DK
  • 12 Department Of Surgery, Odense University Hospital; Danish Pancreatic Cancer Database, Odense/DK

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1769

Background

Nationwide data on the effect of primary treatment on median overall survival (mOS) in an entire unselected population of patients (pts) with pancreatic cancer (PC) have not been reported before. The aim of the present study was to investigate the effect of initial treatment on mOS in all incident pts with PC in Denmark in a recent five-year period (2011 to 2016).

Methods

From 1 May 2011 to 30 April 2016, 4260 pts diagnosed with PC were identified in the national Danish Pancreatic Cancer Database. Last follow up was 10 September 2017. Excluded were 99 pts (2%), 56 due to combined preoperative chemotherapy followed by resection, 22 due to other malignancies, 13 due to incorrect registration of treatment, 6 pts treated with unknown chemotherapy and 2 were lost to follow up, leaving 4161 pts included. The mOS was analysed from the date of the initial treatment, either resection or chemotherapy or from the date of diagnosis in case of best supportive care (BSC).

Results

Initial treatment and mOS for all 4161 pts.Table: 743P

TreatmentPts, No.mOS, months95% CI
Resection*
N + 46617.515.4-20.1
N-21536.928.6-44.7
Chemotherapy
Gem9585.14.8- 5.6
FOLFIRINOX41410.08.9-11.0
GemCap1258.46.8-9.8
GemS11119.07.2-10.3
GemPac857.15.5-9.7
Others539.38.2-14.0
BSC16961.61.5-1.8

Abbreviations: CI: confidence interval, N: lymph node status, without – or with +, Gem: gemcitabine, FOLFIRINOX: 5-flourouracil, leukovorin, irinotecan and oxaliplatin, Cap: capecitabine, S1: tegafur/gimeracil/oteracil, Pac: nab-paclitaxel, others: other regimens. *There were 38 pts without histopathological reports on lymph node status.

Conclusions

The initial resected lymph node negative pts had the longest survival; double that of lymph node positive pts. Pts initially treated with chemotherapy had slightly shorter mOS than found in randomized trials, reflecting patient characteristics in an unselected population. The outcome of gemcitabine monotherapy was poor, possibly reflecting less treatment effect and selection of less fit pts. The BSC group was larger than expected and further investigations, particularly in early diagnosis of PC are of utmost importance.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

The Axel Muusfeldt foundation.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.